HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS - Free Report) in a research report released on Monday morning,Benzinga reports. The brokerage currently has a $26.00 price objective on the stock.
ALMS has been the subject of a number of other reports. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They set an "outperform" rating and a $25.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a report on Thursday, November 14th. Finally, Baird R W upgraded shares of Alumis to a "strong-buy" rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $26.83.
Read Our Latest Stock Report on ALMS
Alumis Stock Up 4.0 %
ALMS stock traded up $0.34 during midday trading on Monday, reaching $8.79. The company had a trading volume of 114,121 shares, compared to its average volume of 88,540. The stock's 50 day moving average price is $9.48. Alumis has a fifty-two week low of $7.46 and a fifty-two week high of $13.53.
Institutional Investors Weigh In On Alumis
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALMS. BNP Paribas Financial Markets bought a new position in Alumis during the 3rd quarter valued at $27,000. MetLife Investment Management LLC bought a new position in Alumis during the third quarter valued at about $89,000. JPMorgan Chase & Co. acquired a new position in Alumis during the third quarter worth about $191,000. Barclays PLC bought a new stake in Alumis in the third quarter worth about $197,000. Finally, Maven Securities LTD bought a new position in shares of Alumis during the 2nd quarter valued at about $332,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Further Reading
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
